These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38762210)

  • 21. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
    Yin X; Liu Z; Wang J
    Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sake lees extract improves hepatic lipid accumulation in high fat diet-fed mice.
    Kubo H; Hoshi M; Matsumoto T; Irie M; Oura S; Tsutsumi H; Hata Y; Yamamoto Y; Saito K
    Lipids Health Dis; 2017 Jun; 16(1):106. PubMed ID: 28578672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Berberine in Non-Alcoholic Fatty Liver Disease-A Review.
    Koperska A; Wesołek A; Moszak M; Szulińska M
    Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
    Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
    Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.
    Yan HM; Xia MF; Wang Y; Chang XX; Yao XZ; Rao SX; Zeng MS; Tu YF; Feng R; Jia WP; Liu J; Deng W; Jiang JD; Gao X
    PLoS One; 2015; 10(8):e0134172. PubMed ID: 26252777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel Alisma orientale extract alleviates non-alcoholic steatohepatitis in mice via modulation of PPARα signaling pathway.
    Xie Y; Jin Y; Wen J; Li G; Huai X; Duan Y; Ni F; Fu J; Li M; Li L; Yan M; Cao L; Xiao W; Yang H; Wang ZZ
    Biomed Pharmacother; 2024 Jul; 176():116908. PubMed ID: 38850668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attenuation by Tetrahydrocurcumin of Adiposity and Hepatic Steatosis in Mice with High-Fat-Diet-Induced Obesity.
    Pan MH; Chen JW; Kong ZL; Wu JC; Ho CT; Lai CS
    J Agric Food Chem; 2018 Dec; 66(48):12685-12695. PubMed ID: 30415544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. α-Lactalbumin Peptide Asp-Gln-Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids-Treated HepG2 Cells and High-Fat Diet-Induced NAFLD Mice by Activating the PPARα Pathway.
    Chen H; Ma Y; Qi X; Tian J; Ma Y; Niu T
    Mol Nutr Food Res; 2023 Aug; 67(16):e2200499. PubMed ID: 37354055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
    Liu J; Tang T; Wang GD; Liu B
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
    [No Abstract]   [Full Text] [Related]  

  • 30. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
    Fu D; Cui H; Zhang Y
    Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Berberine Improves Inflammatory Responses of Diabetes Mellitus in Zucker Diabetic Fatty Rats and Insulin-Resistant HepG2 Cells through the PPM1B Pathway.
    Wu YS; Li ZM; Chen YT; Dai SJ; Zhou XJ; Yang YX; Lou JS; Ji LT; Bao YT; Xuan L; Lin LN; Li CY
    J Immunol Res; 2020; 2020():2141508. PubMed ID: 32908938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
    Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
    J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Berberine Ameliorates Abnormal Lipid Metabolism via the Adenosine Monophosphate-Activated Protein Kinase/Sirtuin 1 Pathway in Alcohol-Related Liver Disease.
    Zhu L; Xu JJ; Li HD; Li JJ; Cheng M; Niu XN; Jia PC; Liu JY; Huang C; Lv XW; Li J
    Lab Invest; 2023 Apr; 103(4):100041. PubMed ID: 36870291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
    Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
    J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats.
    Zhong M; Yan Y; Yuan H; A R; Xu G; Cai F; Yang Y; Wang Y; Zhang W
    Food Funct; 2022 Jul; 13(13):7287-7301. PubMed ID: 35726797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
    Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
    J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism.
    Ma X; Yu X; Li R; Cui J; Yu H; Ren L; Jiang J; Zhang W; Wang L
    J Ethnopharmacol; 2024 Jan; 319(Pt 2):117238. PubMed ID: 37774895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway.
    Wang L; Jia Z; Wang B; Zhang B
    Turk J Gastroenterol; 2020 Dec; 31(12):902-909. PubMed ID: 33626003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Berberine prevents NAFLD and HCC by modulating metabolic disorders.
    Lin X; Zhang J; Chu Y; Nie Q; Zhang J
    Pharmacol Ther; 2024 Feb; 254():108593. PubMed ID: 38301771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
    Xiao Z; Chu Y; Qin W
    Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.